Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 5 | History Defined

Is Wall Street Bullish or Bearish on Kenvue Stock?

Despite Kenvue trailing the broader market over the past year, Wall Street analysts maintain a moderately bullish outlook on the stock's potential.

Barchart

How Is Kenvue’s Stock Performance Compared to Other Consumer Defensive Stocks

With Kenvue slightly lagging behind other consumer defensive stocks over the past year, Wall Street remains cautiously optimistic about its prospects.

Barchart

Johnson & Johnson Risks UK Lawsuit Over Talc Cancer Claim

UK claimants announced Wednesday legal action against US pharmaceutical and cosmetics giant Johnson & Johnson, alleging that women diagnosed with cancers were exposed to asbestos in the company's talcum powder.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

What’s Behind the Rally in Kenvue Stock Today?

Starboard Value is reportedly eyeing changes at KVUE as the stock underperforms the broader market.

Barchart

Kenvue Stock: Is KVUE Outperforming the Consumer Defensive Sector?

Kenvue has recently outperformed the consumer defensive sector, and Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

3 Defensive Dividend Stocks to Protect Against Pre-Election Volatility

As the U.S. presidential election nears, here are three defensive dividend-paying stocks to help shield your portfolio from pre-election volatility.

Barchart

This Dividend Aristocrat Just Had Its Best Day Ever After Earnings

This dividend aristocrat crushed Q2 earnings and issued strong guidance, and still has some fuel left in the tank for more growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Dividend Stocks Set to Triple Your Income in the Next Decade

Looking for a lifetime of increasing dividends? Here's 3 stocks that could fit the bill.

Barchart

This Morning’s Dr Zoe Williams: Nobody should be smoking at home where there’s a child or pregnant mother

Quitting smoking can be extremely difficult, but there are lots of treatments options out there to help.

The Independent UK

What to Expect From Kenvue's Q2 2024 Earnings Report

Kenvue is all set to announce its second-quarter results this month, and analysts forecast a single-digit decline in the company’s bottom-line figure.

Barchart

Is Kenvue Stock Underperforming the Dow?

While Kenvue's shares have notably lagged behind the Dow Jones in the past year, analysts hold a moderately bullish outlook on the stock.

Barchart

3 High-Yield Dividend Stocks to Build a Passive Income Stream

When the market pulls back, it's an opportunity to invest in high-yield dividend stocks like Kenvue, Enterprise Products Partners, and Verizon, which offer attractive yields and growth potential.

Barchart

Kenvue Stock: Is Wall Street Bullish or Bearish?

Despite Kenvue lagging behind the broader market, Wall Street analysts remain optimistic about the stock’s prospects.

Barchart

Stock market today: Asian shares gain after Wall Street ticks higher amid rate-cut hopes

Asian shares have mostly advanced after Wall Street ticked higher amid hopes that Japan's moves to keep interest rates easy for investors could augur similar trends in the rest of the world

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

Fortune

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

Fortune

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

Barchart

Johnson & Johnson Stock Looks Like Good Value Now

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

Barchart

Unusual Options Activity in Johnson & Johnson Post Its Kenvue Spinoff Highlights Its Value

An unusual number of out-of-the-money put options in Johnson & Johnson come after the Aug. 30 spinoff of its consumer Kenvue business. This could be a good income play for short-put traders.

Barchart

Kenvue Joins S&P 500 on Friday: Time to Buy?

S&P Dow Jones Indices announced on Monday that Kenvue would join the S&P 500 on Friday. Tuesday’s volume and rising share price suggest that investors feel now is the time to buy its stock.

Barchart

Strength in Technology Stocks Leads the Overall Market Higher

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.69%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.65%. Stocks on Monday settled mostly higher on a rally...

Barchart

Stocks Mixed as Bond Yields Climb

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.65%. Stocks this morning are mixed. An increase in M&A...

Fortune

Newest Fortune 500 member says large companies lose focus: 'You are little more remote from where the action is'

Kenvue, spun off from Johnson & Johnson in May, generated $15 billion in sales last year, enough to put it at rank 275 on 2022's Fortune 500 list.

Kiplinger

Johnson & Johnson Spins Off Kenvue in Biggest IPO Haul Since 2021

Johnson & Johnson rips off Band-Aid and spits out Listerine in a bid to boost margins.

1 … 3 4 5 6

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.